Shield Bio

Clinicians lack fast, reliable genomic sequencing at the point of care to guide precision treatment, especially for infectious disease and sepsis.

A proprietary platform that delivers reliable nanopore (3rd-generation) sequencing results in under a minute in clinical settings.

Hospitals and clinical labs treating infectious diseases and sepsis use the platform to inform patient care.